Heart failure (HF) is a public health problem, being an important and progressively increasing cost not only for the health care system but also for the patient. HF uses about 1-2% of healthcare resources, mainly due to repeated hospitalization and prolonged stays in hospital. Demographic changes and the epidemiological transition of non-communicable diseases mean that HF will increase significantly, thus becoming an ever-increasing public health problem in the near future. Numerous studies, carried out in different countries and in different clinical-pathological contexts, confirm the multifactorial characteristic of HF syndrome due to the presence of etherogenous co-pathologies that determine not only its clinical expression, but, more and more often, its worsening and the need for hospitalization for acute events. The Working Group HEART FAILURE concentrates its efforts on obtaining data from clinical studies that can improve the prognosis for this condition. Research studies are based on these two approaches:
- Clinical approach: it is aimed at collecting clinical and outcome information in hospitalized patients admitted for acute decompensated HF. This will be obtained through the development of registries that will provide for the first time significant clinical information on selected patient sub-populations not adequately represented in traditional clinical trials and will allow the creation of a unique tool for health management strategies
- Translational approach: it is aimed at validating diagnostic and prognostic markers in the progression of HF to be used in clinical practice. At present the potential role of SPB (Surfactant Protein B) as a both diagnostic and prognostic marker Is under evaluation (SPB study).
The Working Group is also interested in the following topics:
- Polyptherapeutical approach to HF;
- Kinetics of biomarkers of pulmonary edema;
- Multiparametric approach to chronic HF;
- Sleep disorders and chronic HF;
- Pulmonary hypertension.
- The FAiling HearT in the Elderly (FATE) Registry (PI: Gaia Cattadori, MultiMedica)
- Validation of type B pulmonary surfactant protein levels as a diagnostic and prognostic marker in heart failure progression (SPB-HF) cardiaco (PI: Piergiuseppe Agostoni, Monzino)
Prof. Piergiuseppe Agostoni
IRCCS Centro Cardiologico Monzino
POLICLINICO SAN DONATO Marco Guazzi – MULTIMEDICA Gaia Cattadori – AUXOLOGICO Alessandra Villani – FONDAZIONE CA’ GRANDA Marco Vicenzi – OSPEDALE SAN RAFFAELE Paolo Camici – MARIO NEGRI Lidia Staszewsky – OSPEDALE PEDIATRICO BAMBINO GESU’ Rachele Adorisio – POLICLINICO SAN MATTEO Carlo Pellegrini – FONDAZIONE MAUGERI Maria Teresa La Rovere – HUMANITAS Cristina Panico – SAN RAFFAELE PISANA Maurizio Volterrani – ISMETT IRCCS Piero Levantino – SDN Carlo Cavaliere – NEUROMED Giuseppe Lembo – IRCCS OSPEDALE POLICLINICO SAN MARTINO Pietro Ameri – ISTITUTO GIANNINA GASLINI Maria Derchi – IRCCS POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI Domenico D’Amario